These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36248993)

  • 1. Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers - current evidence and future directions.
    Lam RCT; Johnson D; Lam G; Li MLY; Wong JWL; Lam WKJ; Chan KCA; Ma B
    Front Oncol; 2022; 12():970242. PubMed ID: 36248993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC).
    Masfarré L; Vidal J; Fernández-Rodríguez C; Montagut C
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.
    Malla M; Loree JM; Kasi PM; Parikh AR
    J Clin Oncol; 2022 Aug; 40(24):2846-2857. PubMed ID: 35839443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC).
    Chakrabarti S; Kasi AK; Parikh AR; Mahipal A
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma.
    Fu Y; Xu Y; Liu W; Zhang J; Wang F; Jian Q; Huang G; Zou C; Xie X; Kim AH; Mathios D; Pang F; Li F; Wang K; Shen J; Yin J
    EClinicalMedicine; 2024 Jul; 73():102697. PubMed ID: 39022798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives.
    Moati E; Taly V; Garinet S; Didelot A; Taieb J; Laurent-Puig P; Zaanan A
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine.
    Pellini B; Pejovic N; Feng W; Earland N; Harris PK; Usmani A; Szymanski JJ; Qaium F; Mudd J; Petty M; Jiang Y; Singh A; Maher CA; Henke LE; Park H; Ciorba MA; Kim H; Mutch MG; Pedersen KS; Tan BR; Hawkins WG; Fields RC; Chaudhuri AA
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
    Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
    JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal Cancers.
    Lee MS; Kaseb AO; Pant S
    Clin Cancer Res; 2023 Sep; 29(17):3267-3274. PubMed ID: 37092904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of circulating tumour DNA analysis for gastrointestinal cancers.
    Nakamura Y; Shitara K
    ESMO Open; 2020 Jan; 5(Suppl 1):e000600. PubMed ID: 32830648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
    Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
    Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer.
    Reece M; Saluja H; Hollington P; Karapetis CS; Vatandoust S; Young GP; Symonds EL
    Front Genet; 2019; 10():1118. PubMed ID: 31824558
    [No Abstract]   [Full Text] [Related]  

  • 15. Mind the target: circulating tumour DNA in gastrointestinal malignancies.
    Fontana E; Ignatova E
    Curr Opin Oncol; 2022 Jul; 34(4):395-402. PubMed ID: 35837709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients.
    Nguyen HT; Nguyen TV; Nguyen Hoang VA; Tran DH; Le Trinh NA; Le MT; Nguyen Tran TA; Pham TH; Dinh TC; Nguyen TS; Nguyen The KC; Mai H; Chu MT; Pham DH; Nguyen XC; Ngo Ha TM; Nguyen DS; Nguyen DQ; Lu YT; Do Thi TT; Truong DK; Nguyen QT; Nguyen HN; Giang H; Tu LN
    Front Oncol; 2022; 12():1069296. PubMed ID: 36578946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. State of the Art: ctDNA in Upper Gastrointestinal Malignancies.
    Labiano I; Huerta AE; Arrazubi V; Hernandez-Garcia I; Mata E; Gomez D; Arasanz H; Vera R; Alsina M
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor DNA analysis predicts recurrence and avoids unnecessary adjuvant chemotherapy in I-IV colorectal cancer.
    Fan W; Xia Z; Chen R; Lin D; Li F; Zheng Y; Luo J; Xiong Y; Yu P; Gao W; Gong Y; Zhang F; Zhang S; Li L
    Ther Adv Med Oncol; 2024; 16():17588359231220607. PubMed ID: 38282662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.
    Bent A; Raghavan S; Dasari A; Kopetz S
    Clin Colorectal Cancer; 2022 Jun; 21(2):89-95. PubMed ID: 35450837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.